person · Reporting owner

Smith Karen L.

Disclosed activity across 11 companies

Tapewire entity: 35091
SEC CIK: 0001639637

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aurinia Pharmaceuticals Inc.AUPH · Entity 4463	Director	November 21, 2024	November 25, 2024
Context Therapeutics Inc.CNTX · Entity 7406	Director	June 24, 2026	June 26, 2026
Emergent BioSolutions Inc.EBS · Entity 5902	EVP, Chief Medical Officer	May 07, 2021	May 11, 2021
Jazz Pharmaceuticals plcJAZZ · Entity 818	EVP, R&D and CMO	March 05, 2018	March 07, 2018
Quince Therapeutics, Inc.QNCX · Entity 7403	Chief Medical Officer	February 01, 2023	February 02, 2023
SANGAMO THERAPEUTICS, INCSGMO · Entity 7038	Director	June 12, 2025	June 16, 2025
Skye Bioscience, Inc.SKYE · Entity 8098	Director	March 31, 2026	April 02, 2026
Tourmaline Bio, Inc.TALS · Entity 15643	Director	June 13, 2023	June 14, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aurinia Pharmaceuticals Inc.

Report date November 21, 2024 · Filed November 25, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	24,807	Reported balance After 2024-11-21 transaction · row 1 1 source row Row 1 · 2024-11-21 · Grant · Acquired 12,135 · Balance 24,807 F1: Represents grant of Restricted Stock Units (RSUs) payable solely in common shares of the Issuer. The shares subject to the RSUs shall vest one year from date of grant.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.24 · Expires 2034-11-21	Direct	18,641	Reported balance After 2024-11-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-11-21 · Grant · Acquired 18,641 · Balance 18,641 F2: The options shall vest one year from date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Represents grant of Restricted Stock Units (RSUs) payable solely in common shares of the Issuer. The shares subject to the RSUs shall vest one year from date of grant.

F2: The options shall vest one year from date of grant.

Context Therapeutics Inc.

Report date June 24, 2026 · Filed June 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2036-06-23	Direct	45,000	Reported balance After 2026-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-24 · Grant · Acquired 45,000 · Balance 45,000 F1: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.

Emergent BioSolutions Inc.

Report date May 07, 2021 · Filed May 11, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,888	Reported balance After 2021-05-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-05-07 · Tax withholding · Disposed 305 · Balance 11,888 F1: Represents shares of common stock withheld to pay taxes upon vest of restricted stock units granted under the company's stock incentive plan, as amended and restated.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock withheld to pay taxes upon vest of restricted stock units granted under the company's stock incentive plan, as amended and restated.

Jazz Pharmaceuticals plc

Report date March 05, 2018 · Filed March 07, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	28,474	Reported balance After 2018-03-05 transaction · row 1 1 source row Row 1 · 2018-03-05 · Tax withholding · Disposed 648 · Balance 28,474 F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

Quince Therapeutics, Inc.

Report date February 01, 2023 · Filed February 02, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.94 · Expires 2033-01-31	Direct	225,000	Reported balance After 2023-02-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-02-01 · Grant · Acquired 225,000 · Balance 225,000 F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.

SANGAMO THERAPEUTICS, INC

Report date June 12, 2025 · Filed June 16, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	102,100	Reported balance After 2025-06-12 transaction · row 1 1 source row Row 1 · 2025-06-12 · Grant · Acquired 25,000 · Balance 102,100 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2035-06-11	Direct	50,000	Reported balance After 2025-06-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-06-12 · Grant · Acquired 50,000 · Balance 50,000 F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.

F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Skye Bioscience, Inc.

Report date March 31, 2026 · Filed April 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2036-03-31	Direct	75,000	Reported balance After 2026-03-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-03-31 · Grant · Acquired 75,000 · Balance 75,000 F1: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.

Tourmaline Bio, Inc.

Report date June 13, 2023 · Filed June 14, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.54 · Expires 2033-06-13	Direct	20,500	Reported balance After 2023-06-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-13 · Grant · Acquired 20,500 · Balance 20,500 F1: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACCELERON PHARMA INC

Report date November 19, 2021 · Filed November 22, 2021

Section 16 reporting ended · disclosed 2021-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-11-19 transaction · row 1 1 source row Row 1 · 2021-11-19 · Other · Disposed 1,622 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $35.34	Direct	Reported balance After 2021-11-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-11-19 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $40.61	Direct	Reported balance After 2021-11-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-11-19 · Disposition to issuer · Disposed 1,875 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.64	Direct	Reported balance After 2021-11-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-11-19 · Disposition to issuer · Disposed 3,750 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.99	Direct	Reported balance After 2021-11-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-11-19 · Disposition to issuer · Disposed 4,085 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.53	Direct	Reported balance After 2021-11-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-11-19 · Disposition to issuer · Disposed 3,222 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.

ANTARES PHARMA, INC.

Report date May 24, 2022 · Filed May 26, 2022

Section 16 reporting ended · disclosed 2022-05-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-05-24 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-05-24 · Disposition to issuer · Disposed 54,193 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-05-24 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2022-05-24 · Disposition to issuer · Disposed 25,452 · Balance 0 F3: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.72	Direct	Reported balance After 2022-05-24 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-05-24 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.92	Direct	Reported balance After 2022-05-24 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-05-24 · Disposition to issuer · Disposed 46,729 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.73	Direct	Reported balance After 2022-05-24 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-05-24 · Disposition to issuer · Disposed 58,246 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.42	Direct	Reported balance After 2022-05-24 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-05-24 · Disposition to issuer · Disposed 48,542 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").

F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F3: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.

F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.

Sucampo Pharmaceuticals, Inc.

Report date February 13, 2018 · Filed February 13, 2018

Section 16 reporting ended · disclosed 2018-02-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.95 · Expires 2027-07-15	Direct	0	Reported balance After 2018-02-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-02-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 24, 2026 Filed Jun 26, 2026 20:20 UTC	Context Therapeutics Inc. CNTX · Entity 7406	GrantStock Option (right to buy) · Derivative	45,000	$0.00 Strike: $0.58	$0.00	Disclosure SEC source: 0001628280-26-045778 · wk-form4_1782505215.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document
March 31, 2026 Filed Apr 2, 2026 22:22 UTC	Skye Bioscience, Inc. SKYE · Entity 8098	GrantStock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $0.62	$0.00	Disclosure SEC source: 0001628280-26-023358 · wk-form4_1775168549.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. Read SEC document
February 06, 2026 Filed Feb 10, 2026 01:54 UTC	Skye Bioscience, Inc. SKYE · Entity 8098	GrantStock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $0.82	$0.00	Disclosure SEC source: 0001628280-26-006625 · wk-form4_1770688487.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026. Read SEC document
June 12, 2025 Filed Jun 12, 2025 21:27 UTC	Context Therapeutics Inc. CNTX · Entity 7406	GrantStock Option (right to buy) · Derivative	123,500	$0.00 Strike: $0.65	$0.00	Disclosure SEC source: 0001842952-25-000076 · wk-form4_1749763615.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,500 Underlying: Common Stock · 123,500 shares Expires 2035-06-11 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 12, 2026 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2026 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document
June 12, 2025 Filed Jun 16, 2025 20:05 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $0.50	$0.00	Disclosure SEC source: 0001415889-25-017374 · form4-06162025_040615.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-11 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document
June 12, 2025 Filed Jun 16, 2025 20:05 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001415889-25-017374 · form4-06162025_040615.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,100 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document
February 24, 2025 Filed Feb 26, 2025 22:45 UTC	Skye Bioscience, Inc. SKYE · Entity 8098	GrantStock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $2.89	$0.00	Disclosure SEC source: 0001516551-25-000012 · wk-form4_1740609908.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning February 21, 2025. Read SEC document
November 21, 2024 Filed Nov 25, 2024 21:38 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantDirector Stock Option (right to buy) · Derivative	18,641	$0.00 Strike: $8.24	$0.00	Disclosure SEC source: 0001600620-24-000126 · wk-form4_1732570731.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,641 Underlying: Common Shares · 18,641 shares Expires 2034-11-21 F2 · derivative.exercise_date: The options shall vest one year from date of grant. Read SEC document
November 21, 2024 Filed Nov 25, 2024 21:38 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantCommon Shares	12,135	$0.00	$0.00	Disclosure SEC source: 0001600620-24-000126 · wk-form4_1732570731.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,807 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common shares of the Issuer. The shares subject to the RSUs shall vest one year from date of grant. Read SEC document
November 11, 2024 Filed Nov 13, 2024 00:20 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	SaleCommon Stock	5,241	$8.43	$44,181.63	Disclosure SEC source: 0001600620-24-000114 · wk-form4_1731457229.xml · nonDerivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,672 F2 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.37 to $8.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document
November 08, 2024 Filed Nov 13, 2024 00:20 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	Exercise / conversionRestricted Stock Units · Derivative	17,913	$0.00	$0.00	Disclosure SEC source: 0001600620-24-000114 · wk-form4_1731457229.xml · derivative · entry 3 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs vested one year from date of grant and have no expiration date. F4 · derivative.expiration_date: The RSUs vested one year from date of grant and have no expiration date. Read SEC document
November 08, 2024 Filed Nov 13, 2024 00:20 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	Exercise / conversionCommon Stock	17,913	Not disclosed	Not disclosed	Disclosure SEC source: 0001600620-24-000114 · wk-form4_1731457229.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
October 28, 2024 Filed Oct 31, 2024 00:28 UTC	Skye Bioscience, Inc. SKYE · Entity 8098	GrantStock Option (Right to Buy) · Derivative	70,000	$0.00 Strike: $5.15	$0.00	Disclosure SEC source: 0001516551-24-000098 · wk-form4_1730334489.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-10-27 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning October 28, 2024. Read SEC document
September 04, 2024 Filed Sep 5, 2024 12:15 UTC	Context Therapeutics Inc. CNTX · Entity 7406	GrantStock Option (right to buy) · Derivative	19,315	$0.00 Strike: $2.43	$0.00	Disclosure SEC source: 0001842952-24-000079 · wk-form4_1725538497.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,315 Underlying: Common Stock · 19,315 shares Expires 2034-09-03 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 13, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document
July 02, 2024 Filed Jul 5, 2024 12:59 UTC	Skye Bioscience, Inc. SKYE · Entity 8098	GrantDirector Stock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $7.56	$0.00	Disclosure SEC source: 0001516551-24-000068 · wk-form4_1720184343.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-07-01 F1 · derivative.exercise_date: The stock option will vest in equal monthly installments over the one year period from the date of grant. Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:26 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $0.57	$0.00	Disclosure SEC source: 0001415889-24-015762 · form4-06062024_080627.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-03 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:26 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001415889-24-015762 · form4-06062024_080627.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,100 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 4, 2025 or (b) the day prior to the 2025 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document
August 18, 2023 Filed Aug 21, 2023 20:19 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantStock Option (right to buy) · Derivative	28,959	$0.00 Strike: $9.49	$0.00	Disclosure SEC source: 0001600620-23-000034 · wk-form4_1692649179.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,959 Underlying: Common Stock · 28,959 shares Expires 2033-08-18 F2 · derivative.exercise_date: The option vests in twelve equal installments commencing on September 18, 2023. Read SEC document
August 18, 2023 Filed Aug 21, 2023 20:19 UTC	Aurinia Pharmaceuticals Inc. AUPH · Entity 4463	GrantRestricted Stock Units · Derivative	17,913	$0.00	$0.00	Disclosure SEC source: 0001600620-23-000034 · wk-form4_1692649179.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,913 Underlying: Common Stock · 17,913 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest one year from date of grant and have no expiration date. Vested shares will be delivered on August 18, 2024. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest one year from date of grant and have no expiration date. Vested shares will be delivered on August 18, 2024. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest one year from date of grant and have no expiration date. Vested shares will be delivered on August 18, 2024. Read SEC document
June 13, 2023 Filed Jun 14, 2023 23:02 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	GrantStock Option (Right to Buy) · Derivative	20,500	$0.00 Strike: $2.54	$0.00	Disclosure SEC source: 0001209191-23-037192 · doc4.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting. Read SEC document
June 01, 2023 Filed Jun 5, 2023 20:52 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	27,750	$0.00 Strike: $1.11	$0.00	Disclosure SEC source: 0001209191-23-034407 · doc4.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,750 Underlying: Common Stock · 27,750 shares Expires 2033-05-31 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document
June 01, 2023 Filed Jun 5, 2023 20:52 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	13,900	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034407 · doc4.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,100 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the earlier of (a) June 1, 2024 or (b) the day prior to the 2024 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document
February 01, 2023 Filed Feb 2, 2023 23:35 UTC	Quince Therapeutics, Inc. QNCX · Entity 7403	GrantEmployee Stock Option (right to buy) · Derivative	225,000	$0.00 Strike: $0.94	$0.00	Disclosure SEC source: 0001209191-23-006401 · doc4.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. Read SEC document
June 09, 2022 Filed Jun 13, 2022 22:16 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	GrantStock Option (Right to Buy) · Derivative	14,501	$0.00 Strike: $8.45	$0.00	Disclosure SEC source: 0000899243-22-022251 · doc4.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,501 Underlying: Common Stock · 14,501 shares Expires 2032-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting. Read SEC document
May 24, 2022 Filed May 26, 2022 17:26 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	Disposition to issuerStock Option (right to buy) · Derivative	48,542	Not disclosed Strike: $4.42	Not disclosed	Disclosure SEC source: 0000899243-22-019793 · doc4.xml · derivative · entry 6 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,542 shares Expires not disclosed F4 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document
May 24, 2022 Filed May 26, 2022 17:26 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	Disposition to issuerStock Option (right to buy) · Derivative	58,246	Not disclosed Strike: $2.73	Not disclosed	Disclosure SEC source: 0000899243-22-019793 · doc4.xml · derivative · entry 5 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,246 shares Expires not disclosed F4 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document
May 24, 2022 Filed May 26, 2022 17:26 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	Disposition to issuerStock Option (right to buy) · Derivative	46,729	Not disclosed Strike: $2.92	Not disclosed	Disclosure SEC source: 0000899243-22-019793 · doc4.xml · derivative · entry 4 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,729 shares Expires not disclosed F4 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document
May 24, 2022 Filed May 26, 2022 17:26 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	Disposition to issuerStock Option (right to buy) · Derivative	20,000	Not disclosed Strike: $3.72	Not disclosed	Disclosure SEC source: 0000899243-22-019793 · doc4.xml · derivative · entry 3 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F4 · price: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.exercise_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. F4 · derivative.expiration_date: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. Read SEC document
May 24, 2022 Filed May 26, 2022 17:26 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	Disposition to issuerCommon Stock	25,452	$5.60	$142,531.20	Disclosure SEC source: 0000899243-22-019793 · doc4.xml · nonDerivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · security: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2 · kind: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document
May 24, 2022 Filed May 26, 2022 17:26 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	Disposition to issuerCommon Stock	54,193	$5.60	$303,480.80	Disclosure SEC source: 0000899243-22-019793 · doc4.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2 · kind: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document
May 23, 2022 Filed May 24, 2022 00:24 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	GrantEmployee Stock Option (right to buy) · Derivative	1,365,449	$0.00 Strike: $2.98	$0.00	Disclosure SEC source: 0001209191-22-031508 · doc4.xml · derivative · entry 3 Smith Karen L. · CIK 0001639637 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,365,449 Underlying: Common Stock · 1,365,449 shares Expires 2032-05-22 F2 · derivative.exercise_date: The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years. Read SEC document
May 19, 2022 Filed May 24, 2022 00:24 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	GrantEmployee Stock Option (right to buy) · Derivative	151,799	Not disclosed Strike: $0.55	Not disclosed	Disclosure SEC source: 0001209191-22-031508 · doc4.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,799 Underlying: Common Stock · 151,799 shares Expires 2032-03-27 F3 · price: Received in the Merger in exchange for an employee stock option to acquire 1,667,000 shares of Novosteo common stock for $0.05 per share. F2 · derivative.exercise_date: The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years. Read SEC document
May 19, 2022 Filed May 24, 2022 00:24 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	GrantCommon Stock	24,336	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-031508 · doc4.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,336 F1 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer. Read SEC document
May 19, 2022 Filed May 27, 2022 21:37 UTC Amendment	Quince Therapeutics, Inc. CRTX · Entity 7403	GrantCommon Stock	170,354	$0.00	$0.00	Disclosure SEC source: 0001209191-22-032677 · doc4a.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,690 F1 · shares: The shares vest monthly, subject to continued service. F2 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer. Read SEC document
May 16, 2022 Filed May 17, 2022 22:15 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	GrantStock Option (Right to Buy) · Derivative	29,002	$0.00 Strike: $6.54	$0.00	Disclosure SEC source: 0000899243-22-018449 · doc4.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,002 Underlying: Common Stock · 29,002 shares Expires 2032-05-15 F1 · derivative.exercise_date: The shares underlying this option shall vest in three equal installments from the date of grant. Read SEC document
February 25, 2022 Filed Mar 1, 2022 22:14 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $5.90	$0.00	Disclosure SEC source: 0001209191-22-014157 · doc4.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-24 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document
February 25, 2022 Filed Mar 1, 2022 22:14 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	12,500	$0.00	$0.00	Disclosure SEC source: 0001209191-22-014157 · doc4.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,200 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document
November 19, 2021 Filed Nov 22, 2021 09:09 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Disposition to issuerOption to Purchase Common Stock · Derivative	3,222	Not disclosed Strike: $115.53	Not disclosed	Disclosure SEC source: 0001104659-21-142277 · tm2133601-10_4seq1.xml · derivative · entry 6 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,222 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document
November 19, 2021 Filed Nov 22, 2021 09:09 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Disposition to issuerOption to Purchase Common Stock · Derivative	4,085	Not disclosed Strike: $52.99	Not disclosed	Disclosure SEC source: 0001104659-21-142277 · tm2133601-10_4seq1.xml · derivative · entry 5 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,085 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document
November 19, 2021 Filed Nov 22, 2021 09:09 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Disposition to issuerOption to Purchase Common Stock · Derivative	3,750	Not disclosed Strike: $41.64	Not disclosed	Disclosure SEC source: 0001104659-21-142277 · tm2133601-10_4seq1.xml · derivative · entry 4 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document
November 19, 2021 Filed Nov 22, 2021 09:09 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Disposition to issuerOption to Purchase Common Stock · Derivative	1,875	Not disclosed Strike: $40.61	Not disclosed	Disclosure SEC source: 0001104659-21-142277 · tm2133601-10_4seq1.xml · derivative · entry 3 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,875 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document
November 19, 2021 Filed Nov 22, 2021 09:09 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Disposition to issuerOption to Purchase Common Stock · Derivative	10,000	Not disclosed Strike: $35.34	Not disclosed	Disclosure SEC source: 0001104659-21-142277 · tm2133601-10_4seq1.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document
November 19, 2021 Filed Nov 22, 2021 09:09 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherCommon Stock	1,622	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-21-142277 · tm2133601-10_4seq1.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document
June 10, 2021 Filed Jun 14, 2021 18:27 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	GrantStock Option (right to buy) · Derivative	48,542	$0.00 Strike: $4.42	$0.00	Disclosure SEC source: 0001209191-21-040340 · doc4.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,542 Underlying: Common Stock · 48,542 shares Expires 2031-06-10 F2 · shares: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan. F3 · derivative.exercise_date: The options vest and become exercisable one year from the grant date. Read SEC document
June 10, 2021 Filed Jun 14, 2021 18:27 UTC	ANTARES PHARMA, INC. ATRS · Entity 126887	GrantCommon Stock	25,452	$4.42	$112,497.84	Disclosure SEC source: 0001209191-21-040340 · doc4.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,645 F1 · shares: Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest one year from the grant date. Read SEC document
May 07, 2021 Filed May 11, 2021 20:30 UTC	Emergent BioSolutions Inc. EBS · Entity 5902	Tax withholdingCommon Stock	305	$60.85	$18,559.25	Disclosure SEC source: 0001367644-21-000081 · wf-form4_162076498795882.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,888 F1 · security: Represents shares of common stock withheld to pay taxes upon vest of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document
April 05, 2021 Filed Apr 5, 2021 20:17 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionOption to Purchase Common Stock · Derivative	2,050	$0.00 Strike: $52.99	$0.00	Disclosure SEC source: 0001179110-21-004223 · edgar.xml · derivative · entry 8 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,085 Underlying: Common Stock · 2,050 shares Expires 2030-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date. Read SEC document
April 05, 2021 Filed Apr 5, 2021 20:17 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionOption to Purchase Common Stock · Derivative	1,875	$0.00 Strike: $41.64	$0.00	Disclosure SEC source: 0001179110-21-004223 · edgar.xml · derivative · entry 7 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1,875 shares Expires 2029-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date. Read SEC document
April 05, 2021 Filed Apr 5, 2021 20:17 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionOption to Purchase Common Stock · Derivative	5,000	$0.00 Strike: $35.34	$0.00	Disclosure SEC source: 0001179110-21-004223 · edgar.xml · derivative · entry 6 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2027-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant. Read SEC document
April 05, 2021 Filed Apr 5, 2021 20:17 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	641	$141.15	$90,477.15	Disclosure SEC source: 0001179110-21-004223 · edgar.xml · nonDerivative · entry 5 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,622 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.01 to $141.34 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.